GP2 and pancreatic neoplasm: Given that a very high frequency (>93%) of KRAS mutations has been observed in pancreatic cancer patients15, elucidating interactions among GP2 variants, KRAS oncogenic mutations, and other potential effector genes would provide insights into pancreatic carcinogenesis.